

Medicare National Coverage Determination (NCD)

Topic: Transcatheter Aortic Valve Replacement (TAVR)

Decision: Effective June 21, 2019, CMS will continue to cover TAVR under Coverage with Evidence Development (CED) when the procedure is furnished for the treatment of symptomatic aortic stenosis and according to an FDA approved indication for use with an approved device, in addition to the coverage criteria outlined in the NCD Manual.

What this means: Effective for claims with dates of service on and after June 21, 2019 and later.

For more information, contact Customer Service at the number listed on your ID card.

This announcement can be found at:

<https://www.cms.gov/files/document/r217ncd.pdf>

Effective date: June 21, 2019